Several initiatives are ongoing to facilitate implementation of BBM testing in the AD diagnostic workflow, such as the Davos Alzheimer's Collaborative (DAC) Accurate Diagnosis project, Clinical Implementation of Amyloid Neurodegeneration and Tau testing in Primary Care (CANTATE‐PC), the AD‐RIDDLE consortium in Europe, and the REAL AD study in Sweden. Here, MAPT is linked to amyloidosis.